LAG3, PDCD1, and CD274 (PDL-1) were down-regulated in CRC (see Figure 6E,F), but CTLA4 and HAVCR2 were up-regulated only in the MSI–CRC group, suggesting a potential benefit from CTLA4 and HAVCR2 inhibitors in that subset only [11] (see Figure 6F). The gene discussed is CTLA4; the disease is colorectal carcinoma.